WASHINGTON - Glaucoma patients and dry-eye sufferers may soon be able to trade their messy eye drops for a contact lens that delivers medication gradually over time, say scientists.
Scientist shall present study results of Epidemic Kerato-Conjunctivitis (EKC) drug at Diseases and Drug Discovery conference
The studies on nanoviricide drug candidates against Epidemic Kerato-Conjunctivitis (EKC) were conducted at the Feinstein Institute for Medical Research of the NSLIJ. Dr. Boniuk will be speaking at the GTC-Bio Conference on Ocular Diseases and Drug Discovery on April 21 in Philadelphia, PA.
Though rare but Pterygia is a common eye condition among people who spend large amounts of time outside without wearing sunglasses or clothing to shade their eyes from ultraviolet rays, particularly for farmers who works in the field for long hours. It usually affects almost 10 percent of people who lives in the tropical regions.
A number of studies conducted by ophthalmologists and social workers on mentally retarded children in India showed that nearly 50 percent of them are plagued by several occular problems.
Sirion Therapeutics, Inc. has announced the result of a clinical comparison study on the FDA approved drug Durezol(TM) and Pred Forte(R). The investigational drug aimed for the potentially blinding eye diseases. They are likely to be used for treatment of problems like inflammation and pain associated with ocular surgery. The results will be presented at the upcoming ophthalmology meetings: At the American Uveitis Society's annual invitational meeting.
Ocular surface disease is a major eye disease among the Indians. But this is the problem nobody seems to be interested in. This drives Dr. Virender S. Sangwan, MS in the L.V. Prasad Eye Institute to come forward to take necessary steps. As a result, he works at trying to make the lives of patients easier through stem cell transplantation at the Institute.And now the hospital has become a ray of hope for many.